,address1,address2,city,zip,country,phone,website,industry,sector,longBusinessSummary,fullTimeEmployees,companyOfficers,compensationAsOfEpochDate,maxAge,priceHint,previousClose,open,dayLow,dayHigh,regularMarketPreviousClose,regularMarketOpen,regularMarketDayLow,regularMarketDayHigh,payoutRatio,beta,forwardPE,volume,regularMarketVolume,averageVolume,averageVolume10days,averageDailyVolume10Day,bid,ask,bidSize,askSize,marketCap,fiftyTwoWeekLow,fiftyTwoWeekHigh,fiftyDayAverage,twoHundredDayAverage,trailingAnnualDividendRate,trailingAnnualDividendYield,currency,enterpriseValue,profitMargins,floatShares,sharesOutstanding,heldPercentInsiders,heldPercentInstitutions,bookValue,priceToBook,lastFiscalYearEnd,nextFiscalYearEnd,mostRecentQuarter,netIncomeToCommon,trailingEps,forwardEps,lastSplitFactor,lastSplitDate,enterpriseToEbitda,exchange,quoteType,symbol,underlyingSymbol,shortName,longName,firstTradeDateEpochUtc,timeZoneFullName,timeZoneShortName,gmtOffSetMilliseconds,currentPrice,recommendationMean,recommendationKey,totalCash,totalCashPerShare,ebitda,totalDebt,quickRatio,currentRatio,debtToEquity,returnOnAssets,returnOnEquity,freeCashflow,operatingCashflow,grossMargins,ebitdaMargins,operatingMargins,financialCurrency,trailingPegRatio
0,Eliot Park Innovation Centre,4 Barling Way,Nuneaton,CV10 7RH,United Kingdom,44 24 7679 6496,https://www.valirx.com,Biotechnology,Healthcare,"ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.",8,"{'maxAge': 1, 'name': 'Dr. Suzanne J. Dilly B.Sc., BSc, Ph.D.', 'age': 44, 'title': 'CEO & Director', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 160850, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,6.6,6.6,6.255,6.69999,6.6,6.6,6.255,6.69999,0.0,1.385885,-3.5752687,215703,215703,338460,214504,214504,6.2,7.0,0,0,6804280,6.0,19.468,6.622,9.3465,0.0,0.0,GBp,5539478,0.0,88363259,102320000,0.1539,0.00137,0.042,158.33334,1672444800,1703980800,1688083200,-2409431,-0.03,-1.86,1:125,1586131200,-2.255,LSE,EQUITY,VAL.L,VAL.L,VALIRX PLC ORD 0.1P,ValiRx plc,1010390400,Europe/London,BST,3600000,6.65,1.0,strong_buy,891246,0.009,-2456019,28836,13.372,13.372,0.73,-0.47222,-0.74394995,-1846218,-2334700,0.0,0.0,0.0,GBP,
1,Eliot Park Innovation Centre,4 Barling Way,Nuneaton,CV10 7RH,United Kingdom,44 24 7679 6496,https://www.valirx.com,Biotechnology,Healthcare,"ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.",8,"{'maxAge': 1, 'name': 'Mr. James Gerry Desler FCA', 'age': 66, 'title': 'CFO, Company Sec. & Exec. Director', 'yearBorn': 1956, 'fiscalYear': 2022, 'totalPay': 53000, 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,6.6,6.6,6.255,6.69999,6.6,6.6,6.255,6.69999,0.0,1.385885,-3.5752687,215703,215703,338460,214504,214504,6.2,7.0,0,0,6804280,6.0,19.468,6.622,9.3465,0.0,0.0,GBp,5539478,0.0,88363259,102320000,0.1539,0.00137,0.042,158.33334,1672444800,1703980800,1688083200,-2409431,-0.03,-1.86,1:125,1586131200,-2.255,LSE,EQUITY,VAL.L,VAL.L,VALIRX PLC ORD 0.1P,ValiRx plc,1010390400,Europe/London,BST,3600000,6.65,1.0,strong_buy,891246,0.009,-2456019,28836,13.372,13.372,0.73,-0.47222,-0.74394995,-1846218,-2334700,0.0,0.0,0.0,GBP,
2,Eliot Park Innovation Centre,4 Barling Way,Nuneaton,CV10 7RH,United Kingdom,44 24 7679 6496,https://www.valirx.com,Biotechnology,Healthcare,"ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.",8,"{'maxAge': 1, 'name': 'Mr. Kumar  Nawani', 'title': 'Head of Operations', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,6.6,6.6,6.255,6.69999,6.6,6.6,6.255,6.69999,0.0,1.385885,-3.5752687,215703,215703,338460,214504,214504,6.2,7.0,0,0,6804280,6.0,19.468,6.622,9.3465,0.0,0.0,GBp,5539478,0.0,88363259,102320000,0.1539,0.00137,0.042,158.33334,1672444800,1703980800,1688083200,-2409431,-0.03,-1.86,1:125,1586131200,-2.255,LSE,EQUITY,VAL.L,VAL.L,VALIRX PLC ORD 0.1P,ValiRx plc,1010390400,Europe/London,BST,3600000,6.65,1.0,strong_buy,891246,0.009,-2456019,28836,13.372,13.372,0.73,-0.47222,-0.74394995,-1846218,-2334700,0.0,0.0,0.0,GBP,
3,Eliot Park Innovation Centre,4 Barling Way,Nuneaton,CV10 7RH,United Kingdom,44 24 7679 6496,https://www.valirx.com,Biotechnology,Healthcare,"ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.",8,"{'maxAge': 1, 'name': 'Dr. Catherine Jane Tralau-Stewart Ph.D.', 'title': 'Chief Scientific Officer & Board Observer', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,6.6,6.6,6.255,6.69999,6.6,6.6,6.255,6.69999,0.0,1.385885,-3.5752687,215703,215703,338460,214504,214504,6.2,7.0,0,0,6804280,6.0,19.468,6.622,9.3465,0.0,0.0,GBp,5539478,0.0,88363259,102320000,0.1539,0.00137,0.042,158.33334,1672444800,1703980800,1688083200,-2409431,-0.03,-1.86,1:125,1586131200,-2.255,LSE,EQUITY,VAL.L,VAL.L,VALIRX PLC ORD 0.1P,ValiRx plc,1010390400,Europe/London,BST,3600000,6.65,1.0,strong_buy,891246,0.009,-2456019,28836,13.372,13.372,0.73,-0.47222,-0.74394995,-1846218,-2334700,0.0,0.0,0.0,GBP,
4,Eliot Park Innovation Centre,4 Barling Way,Nuneaton,CV10 7RH,United Kingdom,44 24 7679 6496,https://www.valirx.com,Biotechnology,Healthcare,"ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.",8,"{'maxAge': 1, 'name': 'Mr. Tarquin  Edwards', 'title': 'Head of Investor Relations & Communications', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,6.6,6.6,6.255,6.69999,6.6,6.6,6.255,6.69999,0.0,1.385885,-3.5752687,215703,215703,338460,214504,214504,6.2,7.0,0,0,6804280,6.0,19.468,6.622,9.3465,0.0,0.0,GBp,5539478,0.0,88363259,102320000,0.1539,0.00137,0.042,158.33334,1672444800,1703980800,1688083200,-2409431,-0.03,-1.86,1:125,1586131200,-2.255,LSE,EQUITY,VAL.L,VAL.L,VALIRX PLC ORD 0.1P,ValiRx plc,1010390400,Europe/London,BST,3600000,6.65,1.0,strong_buy,891246,0.009,-2456019,28836,13.372,13.372,0.73,-0.47222,-0.74394995,-1846218,-2334700,0.0,0.0,0.0,GBP,
5,Eliot Park Innovation Centre,4 Barling Way,Nuneaton,CV10 7RH,United Kingdom,44 24 7679 6496,https://www.valirx.com,Biotechnology,Healthcare,"ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom. The company's lead drug candidates include VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer. Its drug candidates also comprise VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; and BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19. ValiRx plc was incorporated in 2000 and is based in Nuneaton, the United Kingdom.",8,"{'maxAge': 1, 'name': 'Mr. Mark  Treharne', 'title': 'Corp. Devel. Mang.', 'exercisedValue': 0, 'unexercisedValue': 0}",1672444800,86400,2,6.6,6.6,6.255,6.69999,6.6,6.6,6.255,6.69999,0.0,1.385885,-3.5752687,215703,215703,338460,214504,214504,6.2,7.0,0,0,6804280,6.0,19.468,6.622,9.3465,0.0,0.0,GBp,5539478,0.0,88363259,102320000,0.1539,0.00137,0.042,158.33334,1672444800,1703980800,1688083200,-2409431,-0.03,-1.86,1:125,1586131200,-2.255,LSE,EQUITY,VAL.L,VAL.L,VALIRX PLC ORD 0.1P,ValiRx plc,1010390400,Europe/London,BST,3600000,6.65,1.0,strong_buy,891246,0.009,-2456019,28836,13.372,13.372,0.73,-0.47222,-0.74394995,-1846218,-2334700,0.0,0.0,0.0,GBP,
